Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Boosted by Duquesne Family Office LLC

Duquesne Family Office LLC grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 530.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,997,400 shares of the company's stock after purchasing an additional 7,569,450 shares during the period. Teva Pharmaceutical Industries makes up 5.3% of Duquesne Family Office LLC's portfolio, making the stock its 4th biggest position. Duquesne Family Office LLC owned about 0.79% of Teva Pharmaceutical Industries worth $198,303,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Crestline Management LP acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $1,220,000. Cutter Capital Management LP bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $12,891,000. Beverly Hills Private Wealth LLC acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $213,000. BNP Paribas grew its position in Teva Pharmaceutical Industries by 59.8% in the fourth quarter. BNP Paribas now owns 12,655 shares of the company's stock worth $279,000 after acquiring an additional 4,737 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Teva Pharmaceutical Industries by 14.4% during the 4th quarter. BNP Paribas Financial Markets now owns 1,337,470 shares of the company's stock worth $29,478,000 after purchasing an additional 168,699 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on TEVA shares. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $16.13 on Wednesday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a 50-day moving average of $15.09 and a 200-day moving average of $17.47. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a market capitalization of $18.29 billion, a price-to-earnings ratio of -11.13, a PEG ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.